In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
Share Talk Weekly Stock Market News Review, Sunday 11th May 2025
The FTSE 100 edged higher on Friday, closing up 23 points, or 0.3%, at 8,554.80 after a hesitant start, as easing trade war tensions lifted investor sentiment. The mid-cap FTSE
HVO, POLB, IMM, AVCT & OPTI – 5 Junior Stocks With High-Stakes Potential in 2025
In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
Share Talk Weekly Stock Market News Review, Sunday 4th May 2025
The UK’s benchmark FTSE 100 index closed higher on Friday, extending its longest-ever streak of gains.
HVO, POLB, IMM, AVCT & OPTI – 5 Junior Stocks With High-Stakes Potential in 2025
In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
Share Talk Weekly Stock Market News Review, Sunday 23rd March 2025
Growth stock investors had reason to be cheerful: The AIM All-Share climbed 1.2% over the week to 694.97, outperforming the FTSE 100—even as market nerves in the US sent ripples
Transforming Biotech: Insights from Tim McCarthy, CEO of ImmuPharma
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of biotechnology, companies often face unique challenges, particularly when it comes to navigating public markets and
Share Talk Weekly Stock Market News Review, Sunday 16th March 2025
Investors shrugged off pessimism at the close of play on Friday. The FTSE 100 climbed by 1.1%, while the UK-centric FTSE 250 advanced by 1.6%. Gold reached a record high
Immupharma PLC (LON:IMM) proves unique Mechanism of Action-P140
ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology
Share Talk Weekly Stock Market News Review, Sunday 16th February 2025
The FTSE 100 Closed Lower, Dropping 32.26 Points to 8,732.46, as investors on both sides of the Atlantic took profits on their shares today ahead of a U.S. public holiday
RNS Hotlist with Zak Mir: OBE, WCAT, IMM, ORCP, CGO, ONDO, BATS & EEE
The UK economy climbed 0.1% quarter-on-quarter in the three months to December, the Office for National Statistics said. Gross domestic product had been flat in the third-quarter from the second. The fourth-quarter
Immupharma PLC (LON:IMM) Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.